That ordering matters for a man in his 40s who is sleeping badly, snapping at people and wondering whether it is his hormones. If it is stress, ashwagandha has a better trial record than most of the supplement shelf. If testosterone is genuinely low, it is not a treatment and should not delay a blood test. We have covered the testosterone question on its own in does KSM-66 raise testosterone and the extract question in KSM-66 vs Sensoril. This piece reads the stress trials first, then the hormones, then the liver.
What the stress and anxiety trials actually measured
Four placebo-controlled trials do most of the work in any ashwagandha-for-stress argument, and each uses a different branded extract or dose.
| Trial | Extract and daily dose | People | Main stress result vs placebo |
|---|---|---|---|
| Chandrasekhar 2012 [1] | KSM-66 root, 600 mg | 64 adults with chronic stress, 60 days | Perceived Stress Scale down 44.0% vs 5.5%; serum cortisol down 27.9% vs 7.9% |
| Salve 2019 [2] | KSM-66 root, 250 or 600 mg | 60 adults with PSS above 20, 8 weeks | PSS and cortisol fell at both doses; 600 mg clearly stronger on cortisol |
| Lopresti 2019 [3] | Shoden, 240 mg | 60 stressed adults, 60 days | Hamilton Anxiety down 41% vs 24% (p = .040); DASS-21 not significant (p = .096); morning cortisol down 23% vs a 0.5% rise |
| Pandit 2024 [4] | Sensoril root and leaf, 125, 250 or 500 mg | 131 enrolled, 98 analysed, 8 weeks | PSS fell at all three doses |
That is a consistent picture: self-rated stress, clinician-rated anxiety and morning cortisol all fall. Pooled analyses agree. A 2022 meta-analysis of 12 trials and 1,002 people found large standardised reductions in anxiety (SMD −1.55) and stress (SMD −1.75) compared to placebo [5]. A 2025 review in BJPsych Open, limited to people with a diagnosed mental disorder, mostly anxiety disorders, found a smaller but still meaningful effect on anxiety (outlier-corrected SMD −1.13) that held up under a stricter Bayesian model; the depression signal did not [6].
Now the parts the supplement labels leave out.
The effects are too large to take at face value. The 2022 meta-analysis rated the certainty of evidence as low for both outcomes, with heterogeneity of 93.8% for anxiety [5]. The trials disagree about the size of the effect far more than chance explains, and effects this large from small, short trials usually shrink when bigger, independent ones arrive. The direction is believable. The magnitude is not.
The placebo arms barely moved. In Chandrasekhar, the placebo group's stress score fell just 5.5% in two months [1]. A placebo group that hardly improves can mean weak blinding — ashwagandha has a distinctive smell and taste — and none of these trials report checking whether participants could guess their group.
Dropout is not trivial. Pandit enrolled 131 people and analysed 98 [4]. A quarter of the sample missing from a per-protocol analysis is enough to flatter a result.
Almost every trial was supplied or funded by the brand. KSM-66 for Chandrasekhar and Salve was provided by its maker, Ixoreal Biomed [1][2]. Arjuna Natural funded the Shoden trial and supplied the product [3]. Natreon, now part of Kerry Group, funded the Sensoril trial — whose authors also declare no conflicts of interest [4]. Chandrasekhar lists its source of support as "Nil" while naming Ixoreal as the supplier [1]. Funding does not make a result false, but it is why the field still needs a large, independent trial.
Our read: ashwagandha has a better case for stress and anxiety than almost any other herb marketed to men, and it clearly beats the evidence behind most "adaptogen" blends. It is still an 8-week, few-dozen-people evidence base. Worth a trial for a man with no liver disease. Not worth the price of skipping a doctor if the anxiety is severe.
The testosterone numbers, read carefully
Testosterone was a secondary outcome in most of these trials, and the men studied are not the men usually buying the product.
In stressed adults, the testosterone change did not beat placebo. In Lopresti's stress trial, testosterone rose 11.4% in men taking ashwagandha vs 0.1% on placebo — but the difference between the groups was not statistically significant (p = .158) [3]. That is the trial closest to this article's question, and it is a null result on testosterone.
In overweight men aged 40 to 70, there was a modest signal. A 16-week crossover trial in 57 men with mild fatigue gave Shoden or placebo for 8 weeks each [7]. Salivary testosterone rose 14.7% more on ashwagandha (p = .010), and DHEA-S 18% more. But fatigue, vigour, sexual wellbeing and cortisol did not differ from placebo [7]. The trial also used no washout between the two periods, so carry-over cannot be ruled out, and Arjuna Natural funded it [7].
The biggest number comes from young men in the gym. In 57 men aged 18 to 50 starting resistance training, KSM-66 600 mg/day raised serum testosterone by 96.2 ng/dL vs 18.0 ng/dL on placebo over 8 weeks [8]. These were healthy young men, training itself moves testosterone, and Ixoreal supplied the product [8].
The most recent pooled estimate, a 2026 meta-analysis of 23 trials, found ashwagandha raised testosterone in men by an average of 57.43 ng/dL compared to placebo, with no effect in women, and a significant reduction in cortisol (SMD −1.18) [9]. That is a real but small nudge, unlikely to move a man with genuinely low testosterone into a different category. The cortisol effect is the better-supported finding, and it may be why men feel better.
If the question is whether you have low testosterone, ashwagandha is the wrong tool and a blood test is the right one. Testosterone therapy outperforms any supplement for men who actually need it, and it needs proper diagnosis and monitoring. Telehealth services such as PeterMD and Maximus start with labs; MangoRx and DudeMeds bundle labs into a monthly price. Our hormone optimisation hub explains what a proper workup includes.
The liver reports and why regulators are acting
This is what 8-week trials of a few dozen people were never big enough to catch.
The first case series, in 2020, described five people — three in Iceland, two from the US Drug-Induced Liver Injury Network — who developed jaundice 2 to 12 weeks after starting ashwagandha supplements [10]. The injury was cholestatic or mixed, the itching and jaundice lasted 5 to 20 weeks, and liver tests normalised within 1 to 5 months in the four who were followed up. Chemical testing found ashwagandha and no contaminants [10].
A 2023 series from Indian liver centres found 23 patients with ashwagandha-linked liver injury between 2019 and 2022 and reported in detail on the 8 who took a single-ingredient product [11]. Five had pre-existing chronic liver disease; three of those developed acute-on-chronic liver failure, and all three died. Product testing again found no adulteration [11]. A 2026 scoping review counted 25 published patients across 13 papers, including one liver transplant and three deaths, all three in people with cirrhosis [12].
Twenty-five published cases is rare against millions of users, but case reports undercount, and the pattern — weeks of use, jaundice, severe itching — is consistent enough that reviewers now describe a reproducible syndrome [12].
Regulators have moved unevenly:
- Denmark made it illegal to sell products containing ashwagandha. The Danish Veterinary and Food Administration cites a Technical University of Denmark assessment that found possible harm to sex hormones and reproduction in men and women, and possible effects on metabolism, the immune system and the nervous system [13]. A 2025 regulatory review dates the ban to 2023 [14]. Liver injury was not the stated basis.
- The EU has not banned it. Heads of the national food agencies recommended a formal review under Article 8 of Regulation 1925/2006 in June 2024; as of that review it had not been opened [14].
- France (ANSES, April 2024) advised pregnant and breastfeeding women, under-18s and people with liver, thyroid or heart conditions to avoid it [14].
- The Netherlands has notified the European Commission of a draft decree that, according to trade press, would ban the leaf while allowing root products with a warning; the comment period runs to 7 December 2026 [15]. We could not find the official text, so treat the scope as reported, not confirmed.
- In the US, ashwagandha remains a dietary supplement with no pre-market approval [14].
Our position
For a stressed man aged 30 to 60 with a healthy liver, ashwagandha is a reasonable, low-cost thing to try for stress and anxiety, using one of the extracts and doses that were actually tested — 240 to 600 mg/day in the KSM-66 and Shoden trials [1][2][3]. Give it 8 weeks, which is as long as the evidence runs. Judge it by sleep and irritability, not by a testosterone number.
Do not take it if you have liver disease, a thyroid condition, or are on medications your doctor has not checked against it. Stop and get liver tests if you notice itching, dark urine or yellowing of the eyes — in the published cases those came on weeks after starting [10][12].
And if what you actually suspect is low testosterone, test rather than guess. A morning blood test settles the question that a supplement never will. Hims and Roman are worth comparing on price alongside the services above, and you can compare TRT providers side by side.
Frequently asked questions
Does ashwagandha lower cortisol?
In most trials, yes. Morning cortisol fell 23% to 28% on ashwagandha in the KSM-66 and Shoden stress trials, compared to little change on placebo [1][3], and a 2026 meta-analysis agrees [9]. The trials were small and mostly industry-funded.
Is ashwagandha better than placebo for anxiety?
The evidence says yes, with low certainty. Pooled trials show large reductions in anxiety scores vs placebo, but the trials disagree widely on the size of the effect [5]. In people with diagnosed anxiety disorders the effect is smaller but held up under stricter analysis [6].
How much does ashwagandha raise testosterone?
On average about 57 ng/dL in men across 23 trials [9]. In the trial of stressed adults, the rise in men did not beat placebo [3]. It is not a substitute for testosterone therapy in men with confirmed low levels.
Which ashwagandha extract has the most evidence?
KSM-66, a root extract, has the most trials, followed by Shoden and Sensoril, a root-and-leaf extract [1][2][3][4]. No trial has compared them head to head, and each brand funded or supplied its own studies.
Is ashwagandha banned?
It is illegal to sell in Denmark [13]. There is no EU-wide ban, though a formal review has been recommended [14], and the Netherlands has proposed restricting the leaf [15]. It is legal in the US as a dietary supplement.
Can ashwagandha damage your liver?
Rarely, yes. Published cases describe jaundice and severe itching appearing 2 to 12 weeks after starting, usually resolving within months of stopping [10]. Deaths have occurred in people with existing cirrhosis [11][12]. Anyone with liver disease should avoid it.
Sources
- [1] Chandrasekhar, Kapoor and Anishetty, A prospective, randomized double-blind, placebo-controlled study of safety and efficacy of a high-concentration full-spectrum extract of ashwagandha root in reducing stress and anxiety in adults, Indian Journal of Psychological Medicine, 2012
- [2] Salve et al., Adaptogenic and anxiolytic effects of ashwagandha root extract in healthy adults: a double-blind, randomized, placebo-controlled clinical study, Cureus, 2019
- [3] Lopresti et al., An investigation into the stress-relieving and pharmacological actions of an ashwagandha (Withania somnifera) extract, Medicine, 2019
- [4] Pandit et al., Effects of Withania somnifera extract in chronically stressed adults: a randomized controlled trial, Nutrients, 2024
- [5] Akhgarjand et al., Does ashwagandha supplementation have a beneficial effect on the management of anxiety and stress? A systematic review and meta-analysis, Phytotherapy Research, 2022
- [6] Marchi et al., The effect of Withania somnifera on mental health symptoms in individuals with mental disorders: systematic review and meta-analysis, BJPsych Open, 2025
- [7] Lopresti, Drummond and Smith, A randomized, double-blind, placebo-controlled, crossover study examining the hormonal and vitality effects of ashwagandha in aging, overweight males, American Journal of Men's Health, 2019
- [8] Wankhede et al., Examining the effect of Withania somnifera supplementation on muscle strength and recovery: a randomized controlled trial, Journal of the International Society of Sports Nutrition, 2015
- [9] Fornalik et al., Hormonal modulation with Withania somnifera: systematic review and meta-analysis of randomized-controlled trials, Planta Medica, 2026
- [10] Björnsson et al., Ashwagandha-induced liver injury: a case series from Iceland and the US Drug-Induced Liver Injury Network, Liver International, 2020
- [11] Philips et al., Ashwagandha-induced liver injury: a case series from India and literature review, Hepatology Communications, 2023
- [12] McIntyre et al., Ashwagandha-associated liver injury: a scoping review of clinical characteristics and safety considerations, Cureus, 2026
- [13] Fødevarestyrelsen (Danish Veterinary and Food Administration), Ashwagandha i kosttilskud og drikkevarer
- [14] Brendler et al., Ashwagandha: is it safe? Part 1: a regulatory review, Phytotherapy Research, 2025
- [15] NutraIngredients, Ashwagandha, huperzia targeted under proposed Dutch supplement rules, October 6, 2026
Alpha Health Finder Editorial Team
Editorial Team
The Alpha Health Finder editorial team researches and writes evidence-based men's health content. Articles are grounded in cited primary sources and reviewed against a fixed editorial standard before publication. We are a research and directory team — not your prescribing clinicians.
Looking for an online provider?
Find a qualified online provider — compare options vetted and reviewed by Alpha Health Finder.
One email a week. The research, not the hype.
What we published this week, what we changed our minds about, and what it means if you are on a protocol.
No spam, no selling your address. Unsubscribe in one click.




